As of November 6, 2026, Tevogen Inc. is a publicly traded company (Nasdaq: TVGN). Ryan H. Saadi, the chief executive and a director, reports holding 91.1%, a majority of its shares. No bankruptcy or receivership appears in its SEC Form 8-K filings. Founder or officer holdings: Ryan H. Saadi, the chief executive and a director (62%); Kirti Desai, the chief financial officer (6.3%) (Schedule 13D/A, November 4, 2026).
Is this your company?
About to sign with, pay or invest in Tevogen Inc.? See the free Snapshot first.
Free to see. No signup.
Is Tevogen Inc. a real, registered company?
- Tevogen Inc. files with the SEC under CIK 1860871 (its SEC filings).
- Its shares are listed under the ticker TVGN on Nasdaq (also TVGNW) (SEC company record).
- Incorporated in Delaware; business address in Warren, New Jersey, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Tevogen Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Susan Podlogar, Director (Form 8-K filed 2026-11-04). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Saadi Ryan H. (filed 2026-11-04).
Who are Tevogen Inc.'s owners and officers?
Tevogen Inc.: incorporated in Delaware; business address in Warren, New Jersey; industry Biological Products, (No Diagnostic Substances) (Form D, 2026-11-04).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-11-04 | Saadi Ryan H. | 91.1% |
| Schedule 13D/A, 2026-09-16 | Saadi Ryan H. | 74.4% |
| Schedule 13D/A, 2026-09-16 | Kirti Desai | 6.3% |
| Schedule 13D/A, 2026-07-14 | Saadi Ryan H. | 59.7% |
| Schedule 13D/A, 2025-12-16 | Ryan H. Saadi | 62% |
| Schedule 13D/A, 2025-07-25 | Ryan H. Saadi | 64.5% |
Questions about who owns Tevogen Inc.
Who owns Tevogen Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Tevogen Inc.: Saadi Ryan H. (91.1%, Schedule 13D/A, filed 2026-11-04), Ryan H. Saadi (62%, Schedule 13D/A, filed 2025-12-16) and Kirti Desai (6.3%, Schedule 13D/A, filed 2026-09-16).
Who are the largest shareholders of Tevogen Inc.?
By the share each holder's latest filing reports, the largest holders of Tevogen Inc. on this page are Saadi Ryan H. (91.1%), Ryan H. Saadi (62%) and Kirti Desai (6.3%).
When did Saadi Ryan H. buy into Tevogen Inc.?
The filings give report dates, not purchase dates. The earliest filing from Saadi Ryan H. on this page is the Schedule 13D/A, filed 2026-07-14, reporting 59.7%; its latest, Schedule 13D/A filed 2026-11-04, reports 91.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Tevogen Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Tevogen Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tevogen Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-11-04 | Susan Podlogar | Director | departed |
Which insiders own Tevogen Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 61,709,567 shares, 61,705,689 held directly and 3,878 indirectly (Form 4, 2026-11-04).
- , the chief commercial officer: 1,169,618 shares (18.0% of shares outstanding) (Form 4, 2025-07-01).
- , the chief financial officer: 992,983 shares (15.2% of shares outstanding) (Form 4, 2026-09-16).
- , a director: 139,192 shares (2.1% of shares outstanding) (Form 4, 2026-09-15).
- , a director: 131,435 shares (2.0% of shares outstanding) (Form 4, 2026-09-15).
Shares outstanding: 6,511,540 as of 2026-08-10, from the company's latest SEC cover page.
How much has Tevogen Inc. raised?
Latest IPO step: Tevogen Inc. amended its IPO registration (S-1/A, 2024-08-01).
IPO filings: S-1/A, 2024-08-01, S-1/A, 2024-07-23.
Keep reading
More on Tevogen Inc. and the records around it.
Tevogen Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Sep 2026
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/tevogen